Each Maine hospital in the 340B program files a yearly report with the Maine Health Data Organization on how it uses 340B savings for its community, its estimated savings set against its total drug spending, and how it oversees the program. The organization posts the reports and a summary.
Bill
LD 1395
Act
P.L. 2023, ch. 276
Session
2023
Applies to
Hospitals in the 340B program; the Maine Health Data Organization
Limits
Reporting began January 1, 2024. A second report, on acquisition costs and payments, was added in 2025 and is due from July 1, 2026.
each hospital participating in the federal drug pricing program under Section 340B of the federal Public Health Service Act, 42 United States Code, Section 256b
A manufacturer may not deny, restrict or interfere with a 340B drug reaching a 340B contract pharmacy, and may not require a 340B entity to send claims or utilization data. Insurers, pharmacy benefits managers and other payers may not pay a 340B entity less for 340B drugs, set different terms or fees, require a 340B marker on a claim or keep it out of a network.
Act
P.L. 2025, ch. 388, Part P
Session
2025
Applies to
Drug manufacturers; health insurers, pharmacy benefits managers and other third-party payers
Limits
A payer may still use preferred pharmacies where the choice does not rest on 340B status. A claim marker is allowed where federal Medicare or Medicaid authorities, or the state for MaineCare, require one.
With respect to reimbursement of a 340B entity for 340B drugs
Plain-language summaries, not legal advice. Laws change, and court rulings on them are not covered here. Read the state’s own page before you rely on one.